help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2004-0062
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corbani, M.
Right arrow Articles by Meunier, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corbani, M.
Right arrow Articles by Meunier, J.-C.
Endocrinology Vol. 145, No. 6 2876-2885
Copyright © 2004 by The Endocrine Society

Ligand-Regulated Internalization of the Opioid Receptor-Like 1: A Confocal Study

Maithé Corbani, Christophe Gonindard and Jean-Claude Meunier

Institut de Pharmacologie et de Biologie Structurale (M.C., J.-C.M.), Centre National de la Recherche Scientifique, 31017 Toulouse, and the Institut Européen de Biologie Cellulaire (C.G.), 31520 Ramonville-Sainte-Agne, France

Address all correspondence and requests for reprints to: Maithé Corbani, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique-Unité Mixte de Recherche 5089, 205 route de Narbonne 31017 Toulouse cedex 4, France. E-mail: maithe.corbani{at}ipbs.fr.

To better understand opioid receptor-like 1 (ORL1) internalization, we fused the C terminus of ORL1, the nociceptin (noc) receptor, to the N terminus of a green fluorescent protein and used the fusion protein to characterize receptor endocytosis in live human embryonic kidney cells. The fusion altered neither the affinity of the receptor for noc or other ORL1 receptor ligands nor the ability of the receptor to mediate agonist-induced binding of GTP{gamma}35S, i.e. coupling with heterotrimeric G protein. Confocal microscopy showed that the fluorescent receptor was mostly associated (>75%) with the periplasmic membrane. In the presence of 0.1 µM noc, approximately 80% of receptors were internalized, and half-maximum internalization was reached in approximately 12 min at 22 C and approximately 6 min at 37 C. After washing, a normal receptor level was recovered within 70 min at 22 C. The lack of internalization in the presence of 0.45 M sucrose suggests that noc-induced receptor endocytosis mainly occurred via clathrin-coated pits. Coincubation of the recombinant cells with noc and tetramethylrhodamine-transferrin showed that ORL1 was mainly internalized through the endosome compartment. Lofentanil and Ro64-6198 ([(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one]) promoted endocytosis of the fluorescent receptor as efficiently as noc. Among the two ORL1 receptor antagonists, J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one), but not III-BTD, blocked the noc-induced internalization of the fluorescent receptor. Two partial agonists were dramatically less efficient than noc to promote ORL1 internalization. They recruited very little (the pseudopeptide [Phe1{psi}(CH2-NH)Gly2]-noc-(1–13)NH2) or no (the hexapeptide Ac-Arg-Tyr-Tyr-Lys-Trp-Arg-NH2) G protein receptor kinase type 2 coupled to red fluorescent protein 1 at the membrane, suggesting that subsequent receptor phosphorylation necessary for internalization via coated pits is altered. Thus, partial agonists that induce a prolonged cell response without causing substantial receptor internalization may be good tools for further clinical treatments.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
D. R. Kapusta, C. Thorkildsen, V. A. Kenigs, E. Meier, M. M. Vinge, C. Quist, and J. S. Petersen
Pharmacodynamic Characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a Novel, Functionally Selective Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 652 - 660.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. R. Kapusta, M. A. Burmeister, G. Calo', R. Guerrini, H. B. Gottlieb, and V. A. Kenigs
Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 643 - 651.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society